Oncology PulsePoints: Metastatic CRPC ASCO Living Guidelines Updates

The 2024 American Society of Clinical Oncology (ASCO) living guideline update for metastatic castration-resistant prostate cancer (mCRPC) represents more than just the addition of new therapies—it marks a definitive shift toward biomarker-driven treatment sequencing. Vince Sung, PharmD, MBA, BCOP, BCPS, director of pharmacy in oncology and infusion at Ascension St. John in Tulsa, breaks down the 3 practice-changing phase 3 trials incorporated into the update, what they mean for clinical workflow, and why pharmacists are uniquely positioned to bridge the gap between guideline recommendations and real-world implementation.